Genetic Determinants of Hemodynamic Response to Esmolol

Not Applicable

• Conditions: Decrease in Heart Rate Below Baseline Value
• Interventions: Drug: esmolol

• Registration Number: NCT01388036
• Lead Sponsor: Hadassah Medical Organization

Brief Summary

Beta 1 Adrenergic antagonists (beta blockers) have major role in the treatment of CHF, IHD and hypertension. However, there is large interindividual variability in the response to beta blockers.

The hypothesis underlying this study is that genetic differences between individuals will determine the individual response to esmolol, a betablocker that is administered intravenously. Esmolol will be administered intravenously to healthy volunteers, and the effects on heart rate and blood pressure will be monitored. In addition, we will measure plasma renin activity and plasma levels of norepinephrine.

Detailed Description

Not available

Study Timeline

• Status Verified: 2011-07
• Study Start: 2011-07
• Study First Submitted: 2011-07-03
• Study First Submitted QC: 2011-07-05
• Last Update Submitted: 2011-07-05
• Study First Posted: 2011-07-06
• Last Update Posted: 2011-07-06
• Primary Completion: 2015-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• healthy male and female
• able to understand and sign informed consent

Exclusion Criteria

• consumption of any medication
• bradycardia <50 BPM
• hypersensitivity to beta blockers

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
esmolol infusion	esmolol	infusion of esmolol during rest and exercise

Primary Outcome Measures

Name	Time	Method
Change in heart rate during exercise	3 hours	continous measurement of heart rate

Secondary Outcome Measures

Name	Time	Method
change in systolic blood pressure during exercise	3 hours	measurement of systolic blood pressure every 5 minutes

Trial Locations

Locations (1)

Hadassah Hebrew University Medical Center; 🇮🇱 Jerusalem, Israel